|
**Overview**: CMV Interferon-Gamma Release Assay**Introduction**: The Cytomegalovirus Interferon-Gamma Release Assay is a diagnostic tool designed to assess CMV-specific immune response using whole blood samples. In India, CMV infection is highly prevalent (~80-90 percent seropositivity in adults), but cell-mediated immunity (measured by CMV-specific IFN-γ release) is critical for risk stratification in transplant recipients, HIV patients, and pregnant women to predict reactivation or disease severity. High morbidity from under-testing in transplant and immunocompromised settings, limited IGRA labs, delayed antiviral prophylaxis leading to CMV disease, graft loss, or congenital transmission. Per immunology practices aligned with ICMR and Indian Society of Transplantation guidelines, the test employs immunoassay for CMV-specific IFN-γ (with positive/negative controls) over 1-2 days with high specificity, valuable for identifying at-risk individuals for preemptive therapy. This diagnostic falls under immune response screening and targets transplant candidates, HIV patients, or pregnant women with positive CMV IgG, addressing accurate detection to guide monitoring or ganciclovir. With elevated morbidity due to underassessment of CMV immunity, the test supports public health efforts by enabling precise risk stratification and reducing CMV-related complications. Its whole blood-based approach ensures reliable T-cell response evaluation.**Other Names**: CMV IGRA Pnl.**FDA Status**: FDA approved, CLIA certified for immunology/microbiology, compliant with 2025 standards.**Historical Milestone**: CMV IGRA developed for transplant risk; in India, emerging in transplant centers.**Purpose**: The test assesses 3 parameters including CMV-specific IFN-γ to guide immune response evaluation, stratify CMV reactivation risk, inform prophylaxis.**Test Parameters**: 1. CMV-Specific IFN-γ, 2. Positive Control, 3. Negative Control.**Pretest Condition**: No fasting required; patients should have transplant/HIV/pregnancy context.**Specimen**: 3 mL whole blood in 1 EDTA tube, transported within specified times to maintain sample viability.**Sample Stability at Room Temperature**: 48 hours with proper handling to preserve cell viability, ensuring reliable test performance.**Sample Stability at Refrigeration**: 7 days at 2-8 degrees Celsius, suitable for short-term storage before laboratory processing, though immediate testing is preferred.**Sample Stability at Frozen**: Not applicable (fresh sample preferred for IGRA).**Medical History**: Patients should provide details on transplant status, immunosuppression, pregnancy week, CMV serology.**Consent**: Written informed consent is required, detailing the test's purpose, potential risks of undetected low CMV immunity including reactivation, benefits of risk assessment, and minimal discomfort from blood draw.**Procedural Considerations**: The test involves sample processing using immunoassay by trained personnel to ensure sterile technique, avoid hemolysis, and interpret results within 1-2 days using provided controls. Laboratories must maintain a controlled environment, adhere to quality assurance protocols.**Factors Affecting Result Accuracy**: Delays beyond stability periods, improper storage conditions, or immunosuppression can affect results. Correlation with clinical evaluation or additional testing is recommended to confirm findings.**Clinical Significance**: Low CMV-specific IFN-γ indicates high reactivation risk, necessitating specialist input. Adequate response may require follow-up in high-risk.**Specialist Consultation**: Transplant physicians or infectious disease specialists should be consulted for management.**Additional Supporting Tests**: CMV PCR, serology for confirmation.**Test Limitations**: Influenced by overall T-cell function; comprehensive approach required.**References**: Indian Journal of Transplantation 2024, CMV Studies India 2023. |
